FDA Releases Final Guidance on 'Deemed To Be a License' Provision of Biologics Price Competition and Innovation Act

Summary

The FDA has released a final guidance on its interpretation of a provision in the Biologics Price Competition and Innovation Act of 2009, which affects the approval process for biological products. The guidance aims to help sponsors prepare for product development plans that may not receive final approval by the FDA's deadline of March 23, 2020.